Erratum to: Adv Ther DOI 10.1007/s12325-014-0112-1 {#Sec1}
==================================================

The authors of the above-mentioned paper would like to make the following adjustments to their article.

In Table 1, the value in the *Resolved* row in the column *Diarrhea*, *Placebo* \[*n* (%)\] currently reads '73 (52)'. This should read '73 (86)'. The correct version of the table is provided below (Table [1](#Tab1){ref-type="table"}). The sentence 'At Week 72, pirfenidone also reduced the proportion of patients with a 50 m or greater decrement in 6-min walk distance (31% relative reduction vs. placebo) and\...\' in the original article should read 'At Week 72, pirfenidone also reduced the proportion of patients with a 50 m or greater decrement in 6-min walk distance (26% relative reduction vs. placebo) and\...\'. The sentence 'Overall, five (1.4%) and one (0.3%) pirfenidone patients discontinued therapy due to nausea and vomiting, respectively, and two (0.6%) discontinued due to diarrhea\' in the original article should read 'Overall, five (1.4%) and one (0.3%) pirfenidone patients discontinued therapy due to nausea and vomiting, respectively, and two (0.6%) placebo patients discontinued due to diarrhea\'.Table 1Gastrointestinal adverse events in the CAPACITY studiesNauseaDiarrheaDyspepsiaVomitingPirfenidone 2,403 mg/day (*N* = 345)Placebo (*N* = 347)Pirfenidone 2,403 mg/day (*N* = 345)Placebo (*N* = 347)Pirfenidone 2,403 mg/day (*N* = 345)Placebo (*N* = 347)Pirfenidone 2,403 mg/day (*N* = 345)Placebo (*N* = 347)Grade 3 or 4 TEAEs, *n* (%)6 (1.7)2 (0.6)2 (0.6)0 (0.0)1 (0.3)2 (0.6)1 (0.3)0 (0.0)TE SAE, *n* (%)0 (0.0)0 (0.0)0 (0.0)1 (0.3)0 (0.0)0 (0.0)0 (0.0)0 (0.0)Deaths, *n*00000000Hospitalizations, *n* (%)0 (0.0)0 (0.0)0 (0.0)1 (0.3)0 (0.0)0 (0.0)0 (0.0)0 (0.0)Discontinuation, *n* (%)5 (1.4)0 (0.0)0 (0.0)2 (0.6)0 (0.0)0 (0.0)1 (0.3)0 (0.0)Dose modification, *n* (%)25 (7.2)7 (2.0)18 (5.2)4 (1.2)8 (2.3)0 (0.0)14 (4.1)3 (0.9)Events, *n*195771538577296217Median duration, days46775168423Resolved, *n* (%)149 (76)65 (84)130 (85)73 (86)40 (52)23 (79)59 (95)17 (100)*TEAE* treatment-emergent adverse event, *TE SAE* treatment-emergent severe adverse event, *Grade 3 TEAE* severe or medically significant but not immediately life-threatening events; hospitalization or prolongation of hospitalization indicated; disabling; limiting self-care Activities of Daily Living, *Grade 4 TEAE* life-threatening consequences; urgent intervention indicated. InterMune data on file

The online version of the original article can be found under doi:10.1007/s12325-014-0112-1.
